TABLE 1.
Clinical indications for breast MR imaging examination by year, 2005 through 2009.
| Year |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2005 | 2006 | 2007 | 2008 | 2009 | Total | |||||||
| Indication for exam | N | % | N | % | N | % | N | % | N | % | N | % |
| DIAGNOSTIC | 459 | (53.2) | 581 | (39.5) | 938 | (41.4) | 871 | (39.8) | 747 | (34.8) | 3596 | (40.3) |
| Additional evaluation | 417 | (48.3) | 495 | (33.6) | 756 | (33.4) | 627 | (28.7) | 575 | (26.8) | 2870 | (32.1) |
| Evaluation of breast problem | 35 | (4.1) | 78 | (5.3) | 156 | (6.9) | 214 | (9.8) | 122 | (5.7) | 605 | (6.8) |
| Recurrence vs. scar | 7 | (0.8) | 8 | (0.5) | 26 | (1.1) | 30 | (1.4) | 50 | (2.3) | 121 | (1.4) |
| SCREENING | 156 | (18.1) | 494 | (33.6) | 742 | (32.8) | 699 | (32.0) | 740 | (34.5) | 2831 | (31.7) |
| BREAST CANCER STAGING/TREATMENT | 128 | (14.8) | 254 | (17.3) | 359 | (15.8) | 321 | (14.7) | 389 | (18.2) | 1451 | (16.3) |
| Evaluation of extent of disease in recent breast cancer diagnosis | 121 | (14.0) | 241 | (16.4) | 340 | (15.0) | 310 | (14.2) | 364 | (17.0) | 1376 | (15.4) |
| Evaluation of response to neoadjuvant chemotherapy | 4 | (0.5) | 9 | (0.6) | 14 | (0.6) | 9 | (0.4) | 25 | (1.2) | 61 | (0.7) |
| Axillary adenopathy (malignant), unknown primary | 3 | (0.3) | 4 | (0.3) | 5 | (0.2) | 2 | (0.1) | 0 | (0.0) | 14 | (0.2) |
| OTHER | 120 | (13.9) | 143 | (9.7) | 225 | (9.9) | 295 | (13.4) | 270 | (12.6) | 1053 | (11.8) |
| Other | 88 | (10.2) | 82 | (5.6) | 146 | (6.4) | 156 | (7.1) | 96 | (4.5) | 568 | (6.4) |
| Short interval follow-up of prior MR | 20 | (2.3) | 49 | (3.3) | 67 | (3.0) | 134 | (6.1) | 158 | (7.4) | 428 | (4.8) |
| Evaluation of implants | 12 | (1.4) | 12 | (0.8) | 12 | (0.5) | 5 | (0.2) | 16 | (0.7) | 57 | (0.6) |
| TOTAL | 863 | (100.0) | 1,472 | (100.0) | 2,264 | (100.0) | 2,186 | (100.0) | 2,146 | (100.0) | 8,931 | (100.0) |